Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Analysis for Diabetic Gastroparesis Patients Treated with GIMOTI® Versus Oral Metoclopramide at the Digestive Disease Week Plenary Session

SOLANA BEACH, Calif., and CHICAGO, IL., February 21, 2023 – Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI^® (metoclopramide) nasal spray, and EVERSANA™, a leading provider of global commercial services to the life science industry, today announced that its abstract entitled “Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide” has been selected for the plenary lecture presentation at the upcoming Digestive Disease Week (DDW 2023). The meeting will take place May 6-9, 2023 at McCormick Place in Chicago, IL.

To read the full press release, click here.